Regulatory Affairs Workload at Drug Development Firms Has Increased Dramatically, According to Tufts Center for the Study of Drug Development
11 mars 2010 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - March 11, 2010) - A growing volume of global drug development and commercialization activity during the past decade has dramatically increased the workload for...
Tufts Center for the Study of Drug Development Launches New Website to Support Research on Critical Drug Development Issues
28 janv. 2010 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 28, 2010) - The Tufts Center for the Study of Drug
Development, the world's leading, independent authority on the nature and
pace of pharmaceutical and biotech drug...
Capacity Planning Is Becoming a Critical Success Factor for Drug Developers, According to Tufts Center for the Study of Drug Development
26 janv. 2010 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 26, 2010) - Growing pressure within the research-based drug
industry to bring new products to market faster and more efficiently is
transforming clinical trial...
U.S. Orphan Product Designations More Than Doubled During Last Decade, According to Tufts Center for the Study of Drug Development
20 janv. 2010 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 20, 2010) - The number of orphan product designations in the
U.S. more than doubled during the last decade, reflecting growing interest
by pharmaceutical and biotech...
Drug Companies Still Under Pressure to Increase Pace of Development, According to Tufts Center for the Study of Drug Development
06 janv. 2010 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 6, 2010) - Although drug developers are improving R&D
efficiency, in part by terminating more unpromising drugs earlier in
development, their continued success...
New Products to Treat Neglected Diseases Are on the Rise, According to Tufts Center for the Study of Drug Development
17 nov. 2009 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 17, 2009) - New products to treat neglected diseases have
received marketing approval from regulatory agencies at a steadily
increasing rate in recent years as...
Top Performing Drug Developers Are Merging Operational and Strategic Objectives, According to Tufts Center for the Study of Drug Development
30 oct. 2009 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - October 30, 2009) - Drug companies racing to develop new products to
replace drugs coming off patent are finding that success is increasingly
tied to the company's ability...
Marketing Exclusivity for First-in-Class Drugs Has Shortened to 2.5 Years, According to Tufts Center for the Study of Drug Development
09 sept. 2009 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 9, 2009) - Marketing exclusivity periods for first-in-class
drugs have fallen dramatically in recent decades -- from a median of 10.2
years in the 1970s to 2.5...
Large Pharmaceutical Firms Are Getting More Drugs Into Development While Terminating Unpromising Candidates, According to Tufts Center for the Study of Drug Development
22 juil. 2009 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 22, 2009) - Large pharmaceutical firms, under pressure to
bring new medicines to market faster, have been getting more drug
candidates into development in recent years...
New Drug R&D Increasingly Depends on Partnerships Between Drug Sponsors and Service Providers, According to Tufts Center for the Study of Drug Development
08 juil. 2009 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 8, 2009) - If drug developers are to remain competitive,
they must rely less on traditional outsourcing, in which external service
providers offer a way to quickly...